{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:12Z","timestamp":1792791432297,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T00:00:00Z","timestamp":1504656000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Turing Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40268-017-0206-8","type":"journal-article","created":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T17:34:32Z","timestamp":1504719272000},"page":"523-544","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":173,"title":["Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0759-1598","authenticated-orcid":false,"given":"Ruben R.","family":"Ben-Harari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Casoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,6]]},"reference":[{"issue":"2","key":"206_CR1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/CMR.11.2.267","volume":"11","author":"JP Dubey","year":"1998","unstructured":"Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev. 1998;11(2):267\u201399.","journal-title":"Clin Microbiol Rev"},{"issue":"12\u201313","key":"206_CR2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0020-7519(00)00124-7","volume":"30","author":"AM Tenter","year":"2000","unstructured":"Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol. 2000;30(12\u201313):1217\u201358.","journal-title":"Int J Parasitol"},{"key":"206_CR3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-2-8178-0847-5_22","volume-title":"Prevention of congenital toxoplasmosis in Austria: experience of 25 years. Congenital toxoplasmosis","author":"H Asp\u00f6ck","year":"2000","unstructured":"Asp\u00f6ck H. Prevention of congenital toxoplasmosis in Austria: experience of 25 years. Congenital toxoplasmosis. New York: Springer; 2000. p. 277\u201392."},{"key":"206_CR4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.preteyeres.2013.12.005","volume":"39","author":"M Maenz","year":"2014","unstructured":"Maenz M, Schluter D, Liesenfeld O, et al. Ocular toxoplasmosis past, present and new aspects of an old disease. Prog Retinal Eye Res. 2014;39:77\u2013106.","journal-title":"Prog Retinal Eye Res"},{"key":"206_CR5","first-page":"125","volume-title":"Handbook of clinical neurology","author":"SK Halonen","year":"2013","unstructured":"Halonen SK, Weiss LM. Toxoplasmosis, Chapter 8. In: Hector H, Garcia HBT, Oscar HDB, editors. Handbook of clinical neurology. New York: Elsevier; 2013. p. 125\u201345."},{"issue":"6","key":"206_CR6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00005792-199411000-00004","volume":"73","author":"C Rabaud","year":"1994","unstructured":"Rabaud C, May T, Amiel C, et al. Extracerebral toxoplasmosis in patients infected with HIV. A French National Survey. Medicine (Baltimore). 1994;73(6):306\u201314.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"206_CR7","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4269\/ajtmh.2010.09-0664","volume":"82","author":"JL Jones","year":"2010","unstructured":"Jones JL, Holland GN. Annual burden of ocular toxoplasmosis in the US. Am J Trop Med Hyg. 2010;82(3):464\u20135.","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"206_CR8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1212\/WNL.0000000000000086","volume":"82","author":"NM Vora","year":"2014","unstructured":"Vora NM, Holman RC, Mehal JM, et al. Burden of encephalitis-associated hospitalizations in the United States, 1998\u20132010. Neurology. 2014;82(5):443\u201351.","journal-title":"Neurology"},{"issue":"6","key":"206_CR9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pedhc.2010.04.008","volume":"25","author":"A Kaye","year":"2011","unstructured":"Kaye A. Toxoplasmosis: diagnosis, treatment, and prevention in congenitally exposed infants. J Pediatr Health Care. 2011;25(6):355\u201364.","journal-title":"J Pediatr Health Care"},{"issue":"14","key":"206_CR10","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/QAD.0000000000001174","volume":"30","author":"G Cuervo","year":"2016","unstructured":"Cuervo G, Simonetti AF, Alegre O, et al. Toxoplasma myocarditis: a rare but serious complication in an HIV-infected late presenter. Aids. 2016;30(14):2253\u20134.","journal-title":"Aids"},{"key":"206_CR11","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/B0-72-160537-0\/50033-5","volume-title":"Infectious diseases of the fetus and newborn infant","author":"JS Remington","year":"2006","unstructured":"Remington JS, McLeod R, Thulliez P, et al. Toxoplasmosis. In: Remington J, Klein J, editors. Infectious diseases of the fetus and newborn infant. 6th ed. Philadelphia: WB Saunders; 2006. p. 947\u20131091.","edition":"6"},{"issue":"9425","key":"206_CR12","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","volume":"363","author":"JG Montoya","year":"2004","unstructured":"Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425):1965\u201376.","journal-title":"Lancet"},{"issue":"Suppl 4","key":"206_CR13","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1086\/430785","volume":"41","author":"P Olliaro","year":"2005","unstructured":"Olliaro P. Drug resistance hampers our capacity to roll back malaria. Clin Infect Dis. 2005;41(Suppl 4):S247\u201357.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"206_CR14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bcpt.12206","volume":"115","author":"MZ Khan Assir","year":"2014","unstructured":"Khan Assir MZ, Ahmad HI, Akram J, et al. An outbreak of pyrimethamine toxicity in patients with ischaemic heart disease in Pakistan. Basic Clin Pharmacol Toxicol. 2014;115(3):291\u20136.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"206_CR15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0002-9394(56)90925-4","volume":"42","author":"VA Beuerman","year":"1956","unstructured":"Beuerman VA, Burnham CJ. Toxoplasmic uveitis; treatment with pyrimethamine and sulfadiazine. Am J Ophthalmol. 1956;42(2):217\u201327.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"206_CR16","first-page":"197","volume":"11","author":"F Lapetina","year":"1989","unstructured":"Lapetina F. Toxoplasmosis and dermatomyositis: a causal or casual relationship? Pediatr Med Chir. 1989;11(2):197\u2013203.","journal-title":"Pediatr Med Chir"},{"issue":"1","key":"206_CR17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3347\/kjp.2016.54.1.31","volume":"54","author":"Z Yang","year":"2016","unstructured":"Yang Z, Ahn HJ, Park YH, et al. Afatinib reduces STAT6 signaling of host ARPE-19 cells infected with Toxoplasma gondii. Korean J Parasitol. 2016;54(1):31\u20138.","journal-title":"Korean J Parasitol"},{"issue":"4","key":"206_CR18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1179\/2047773213Y.0000000094","volume":"107","author":"S Rajapakse","year":"2013","unstructured":"Rajapakse S, Chrishan Shivanthan M, Samaranayake N, et al. Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog Glob Health. 2013;107(4):162\u20139.","journal-title":"Pathog Glob Health"},{"key":"206_CR19","first-page":"CD005420","volume":"3","author":"M Dedicoat","year":"2006","unstructured":"Dedicoat M, Livesley N. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings). Cochrane Database Syst Rev. 2006;3:CD005420.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"206_CR20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/hiv.12402","volume":"18","author":"AV Hernandez","year":"2017","unstructured":"Hernandez AV, Thota P, Pellegrino D, et al. A systematic review and meta-analysis of the relative efficacy and safety of treatment regimens for HIV-associated cerebral toxoplasmosis: is trimethoprim-sulfamethoxazole a real option? HIV Med. 2017;18(2):115\u201324.","journal-title":"HIV Med."},{"issue":"3","key":"206_CR21","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.actatropica.2013.05.006","volume":"127","author":"J Yan","year":"2013","unstructured":"Yan J, Huang B, Liu G, et al. Meta-analysis of prevention and treatment of toxoplasmic encephalitis in HIV-infected patients. Acta Trop. 2013;127(3):236\u201344.","journal-title":"Acta Trop"},{"key":"206_CR22","first-page":"CD002218","volume":"5","author":"E Pradhan","year":"2016","unstructured":"Pradhan E, Bhandari S, Gilbert RE, et al. Antibiotics versus no treatment for toxoplasma retinochoroiditis. Cochrane Database Syst Rev. 2016;5:CD002218.","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"206_CR23","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"FJ Palella Jr","year":"1998","unstructured":"Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853\u201360.","journal-title":"N Engl J Med"},{"key":"206_CR24","first-page":"1","volume":"2017","author":"MP Connolly","year":"2017","unstructured":"Connolly MP, Goodwin E, Schey C, et al. Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis. Pathog Glob Health. 2017;2017:1\u201314.","journal-title":"Pathog Glob Health"},{"issue":"3","key":"206_CR25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bjid.2012.10.030","volume":"17","author":"JE Vidal","year":"2013","unstructured":"Vidal JE, Oliveira AC. AIDS-related cerebral toxoplasmosis in Sao Paulo State, Brazil: marked improvements in the highly active antiretroviral therapy-era but the challenges continue. Braz J Infect Dis. 2013;17(3):379\u201380.","journal-title":"Braz J Infect Dis"},{"issue":"5","key":"206_CR26","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4269\/ajtmh.2011.10-0718","volume":"84","author":"AM Mayor","year":"2011","unstructured":"Mayor AM, Fernandez Santos DM, Dworkin MS, et al. Toxoplasmic encephalitis in an AIDS cohort at Puerto Rico before and after highly active antiretroviral therapy (HAART). Am J Trop Med Hyg. 2011;84(5):838\u201341.","journal-title":"Am J Trop Med Hyg"},{"key":"206_CR27","first-page":"20","volume":"2004","author":"R Fayer","year":"2004","unstructured":"Fayer R, Dubey JP, Lindsay DS. Zoonotic protozoa: from land to sea. Trends Parasitolol. 2004;2004:20.","journal-title":"Trends Parasitolol"},{"issue":"1","key":"206_CR28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archopht.1964.00970010074010","volume":"71","author":"TE Acers","year":"1964","unstructured":"Acers TE, Okla L. Toxoplasmic retinochoroiditis: a double blind therapeutic study. Arch Ophthalmol. 1964;71(1):58\u201362.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"206_CR29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10792-012-9634-1","volume":"33","author":"N Baharivand","year":"2013","unstructured":"Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. Int Ophthalmol. 2013;33(1):39\u201346.","journal-title":"Int Ophthalmol"},{"issue":"5","key":"206_CR30","doi-asserted-by":"crossref","first-page":"Cr296","DOI":"10.12659\/MSM.882735","volume":"18","author":"K Balaskas","year":"2012","unstructured":"Balaskas K, Vaudaux J, Boillat-Blanco N, et al. Azithromycin versus sulfadiazine and pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study. Med Sci Monit. 2012;18(5):Cr296\u2013302.","journal-title":"Med Sci Monit"},{"key":"206_CR31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0002-9394(02)01537-4","volume":"2002","author":"LH Bosch-Driessen","year":"2002","unstructured":"Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;2002:34\u201340.","journal-title":"Am J Ophthalmol"},{"key":"206_CR32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0002-9394(14)74456-3","volume":"1993","author":"A Rothova","year":"1993","unstructured":"Rothova A, Meenken C, Buitenhuis HJ, et al. Therapy for ocular toxoplasmosis. Am J Ophthalmol. 1993;1993:517\u201323.","journal-title":"Am J Ophthalmol"},{"key":"206_CR33","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.ophtha.2005.05.025","volume":"2005","author":"M Soheilian","year":"2005","unstructured":"Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim\/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. 2005;2005:1876\u201382.","journal-title":"Ophthalmology"},{"issue":"1","key":"206_CR34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ophtha.2010.04.020","volume":"118","author":"M Soheilian","year":"2011","unstructured":"Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118(1):134\u201341.","journal-title":"Ophthalmology."},{"key":"206_CR35","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/0002-9394(63)90387-8","volume":"55","author":"CJ Canamucio","year":"1963","unstructured":"Canamucio CJ, Hallett JW, Leopold IH. Recurrence of treated toxoplasmic uveitis. Am J Ophthalmol. 1963;55:1035\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"206_CR36","first-page":"58","volume":"28","author":"S Lam","year":"1993","unstructured":"Lam S, Tessler HH. Quadruple therapy for ocular toxoplasmosis. Can J Ophthalmol. 1993;28(2):58\u201361.","journal-title":"Can J Ophthalmol"},{"issue":"8","key":"206_CR37","doi-asserted-by":"crossref","first-page":"e0004892","DOI":"10.1371\/journal.pntd.0004892","volume":"10","author":"PK Borkowski","year":"2016","unstructured":"Borkowski PK, Brydak-Godowska J, Basiak W, et al. The impact of short-term, intensive antifolate treatment (with pyrimethamine and sulfadoxine) and antibiotics followed by long-term, secondary antifolate prophylaxis on the rate of toxoplasmic retinochoroiditis recurrence. PLoS Negl Trop Dis. 2016;10(8):e0004892.","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"206_CR38","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1055\/s-0042-123717","volume":"234","author":"M Helfenstein","year":"2017","unstructured":"Helfenstein M, Zweifel S, Barthelmes D, et al. Ocular toxoplasmosis: therapy-related adverse drug reactions and their management. Klin Monbl Augenheilkd. 2017;234(4):556\u201360.","journal-title":"Klin Monbl Augenheilk"},{"issue":"1","key":"206_CR39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0002-9394(02)01537-4","volume":"134","author":"LH Bosch-Driessen","year":"2002","unstructured":"Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;134(1):34\u201340.","journal-title":"Am J Ophthalmol"},{"key":"206_CR40","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1086\/339551","volume":"2002","author":"K Chirgwin","year":"2002","unstructured":"Chirgwin K, Hafner R, Leport C, et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237\/ANRS 039 Study. AIDS Clinical Trials Group 237\/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin Infect Dis. 2002;2002:1243\u201350.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"206_CR41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s100960050436","volume":"19","author":"D Podzamczer","year":"2000","unstructured":"Podzamczer D, Miro JM, Ferrer E, et al. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group. Eur J Clin Microbiol Infect Dis. 2000;19(2):89\u201395.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7","key":"206_CR42","first-page":"680","volume":"47","author":"DS Chaddha","year":"1999","unstructured":"Chaddha DS, Kalra SP, Singh AP, et al. Toxoplasmic encephalitis in acquired immunodeficiency syndrome. J Assoc Phys India. 1999;47(7):680\u20134.","journal-title":"J Assoc Phys India"},{"issue":"2","key":"206_CR43","first-page":"113","volume":"44","author":"W Amogne","year":"2006","unstructured":"Amogne W, Teshager G, Zenebe G. Central nervous system toxoplasmosis in adult Ethiopians. Ethiop Med J. 2006;44(2):113\u201320.","journal-title":"Ethiop Med J"},{"issue":"10","key":"206_CR44","first-page":"956","volume":"97","author":"J Arens","year":"2007","unstructured":"Arens J, Barnes K, Crowley N, et al. Treating AIDS-associated cerebral toxoplasmosis\u2014pyrimethamine plus sulfadiazine compared with cotrimoxazole, and outcome with adjunctive glucocorticoids. S Afr Med J. 2007;97(10):956\u20138.","journal-title":"S Afr Med J"},{"issue":"12","key":"206_CR45","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/0956462414560594","volume":"26","author":"RP Goswami","year":"2015","unstructured":"Goswami RP, Goswami RP, Rahman M, et al. Alternative treatment approach to cerebral toxoplasmosis in HIV\/AIDS: experience from a resource-poor setting. Int J STD AIDS. 2015;26(12):864\u20139.","journal-title":"Int J STD AIDS"},{"issue":"3","key":"206_CR46","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1600-0404.1999.tb00735.x","volume":"100","author":"G Arendt","year":"1999","unstructured":"Arendt G, von Giesen HJ, Hefter H, et al. Long-term course and outcome in AIDS patients with cerebral toxoplasmosis. Acta Neurol Scand. 1999;100(3):178\u201384.","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"206_CR47","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/501360","volume":"42","author":"R McLeod","year":"2006","unstructured":"McLeod R, Boyer K, Karrison T, et al. Outcome of treatment for congenital toxoplasmosis, 1981\u20132004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis. 2006;42(10):1383\u201394.","journal-title":"Clin Infect Dis"},{"issue":"26","key":"206_CR48","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1056\/NEJM199406303302604","volume":"330","author":"NG Guerina","year":"1994","unstructured":"Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med. 1994;330(26):1858\u201363.","journal-title":"N Engl J Med"},{"issue":"2","key":"206_CR49","first-page":"87","volume":"57","author":"B Lipka","year":"2011","unstructured":"Lipka B, Milewska-Bobula B, Filipek M. Monitoring of plasma concentration of pyrimethamine (PYR) in infants with congenital Toxoplasma gondii infection\u2014own observations. Wiad Parazytol. 2011;57(2):87\u201392.","journal-title":"Wiad Parazytol"},{"issue":"1","key":"206_CR50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00431-005-1665-4","volume":"165","author":"DR Schmidt","year":"2006","unstructured":"Schmidt DR, Hogh B, Andersen O, et al. Treatment of infants with congenital toxoplasmosis: tolerability and plasma concentrations of sulfadiazine and pyrimethamine. Eur J Pediatr. 2006;165(1):19\u201325.","journal-title":"Eur J Pediatr"},{"issue":"1","key":"206_CR51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jinf.2011.10.008","volume":"64","author":"B Faucher","year":"2012","unstructured":"Faucher B, Garcia-Meric P, Franck J, et al. Long-term ocular outcome in congenital toxoplasmosis: a prospective cohort of treated children. J Infect. 2012;64(1):104\u20139.","journal-title":"J Infect"},{"issue":"5 Pt 1","key":"206_CR52","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0022-3476(89)80660-2","volume":"115","author":"P Hohlfeld","year":"1989","unstructured":"Hohlfeld P, Daffos F, Thulliez P, et al. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr. 1989;115(5 Pt 1):765\u20139.","journal-title":"J Pediatr"},{"issue":"8","key":"206_CR53","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/BF02079067","volume":"154","author":"M Mombro","year":"1995","unstructured":"Mombro M, Perathoner C, Leone A, et al. Congenital toxoplasmosis: 10-year follow up. Eur J Pediatr. 1995;154(8):635\u20139.","journal-title":"Eur J Pediatr"},{"issue":"7","key":"206_CR54","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/archpedi.1980.02130190006003","volume":"134","author":"B Stray-Pedersen","year":"1980","unstructured":"Stray-Pedersen B. Infants potentially at risk for congenital toxoplasmosis: a prospective study. Am J Dis Child. 1980;134(7):638\u201342.","journal-title":"Am J Dis Child"},{"issue":"3","key":"206_CR55","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/00365549850160963","volume":"30","author":"I Villena","year":"1998","unstructured":"Villena I, Aubert D, Leroux B, et al. Pyrimethamine\u2013sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997. Reims Toxoplasmosis Group. Scand J Infect Dis. 1998;30(3):295\u2013300.","journal-title":"Scand J Infect Dis"},{"issue":"11","key":"206_CR56","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/cid\/cis234","volume":"54","author":"A Hotop","year":"2012","unstructured":"Hotop A, Hlobil H, Gross U. Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2012;54(11):1545\u201352.","journal-title":"Clin Infect Dis"},{"key":"206_CR57","doi-asserted-by":"crossref","unstructured":"Carellos EV, de Andrade JQ, Romanelli RM, et al. High frequency of bone marrow depression during congenital toxoplasmosis therapy in a cohort of children identified by neonatal screening in Minas Gerais, Brazil. Pediatr Infect Dis J. 2017 [Epub ahead of print].","DOI":"10.1097\/INF.0000000000001561"},{"issue":"6","key":"206_CR58","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/INF.0000000000001120","volume":"35","author":"J Teil","year":"2016","unstructured":"Teil J, Dupont D, Charpiat B, et al. Treatment of congenital toxoplasmosis: safety of the sulfadoxine\u2013pyrimethamine combination in children based on a method of causality assessment. Pediatr Infect Dis J. 2016;35(6):634\u20138.","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"206_CR59","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bjid.2013.11.009","volume":"18","author":"JD Capobiango","year":"2014","unstructured":"Capobiango JD, Bregano RM, Navarro IT, et al. Congenital toxoplasmosis in a reference center of Parana, Southern Brazil. Braz J Infect Dis. 2014;18(4):364\u201371.","journal-title":"Braz J Infect Dis"},{"issue":"3","key":"206_CR60","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3928\/0090-4481-19940301-07","volume":"23","author":"NG Guerina","year":"1994","unstructured":"Guerina NG. Congenital infection with Toxoplasma gondii. Pediatr Ann. 1994;23(3):138\u201342, 147\u201351.","journal-title":"Pediatr Ann"},{"issue":"6","key":"206_CR61","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/INF.0000000000001120","volume":"35","author":"J Teil","year":"2016","unstructured":"Teil J, Dupont D, Charpiat B, et al. Treatment of congenital toxoplasmosis: safety of the sulfadoxine\u2013pyrimethamine combination in children based on a method of causality assessment. Pediatr Infect Dis J. 2016;35(6):634\u20138.","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"206_CR62","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.clpt.2006.08.016","volume":"80","author":"KI Barnes","year":"2006","unstructured":"Barnes KI, Little F, Smith PJ, et al. Sulfadoxine\u2013pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther. 2006;80(6):582\u201396.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"206_CR63","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/j.1365-2125.2004.02077.x","volume":"57","author":"T Trenque","year":"2004","unstructured":"Trenque T, Simon N, Villena I, et al. Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis. Br J Clin Pharmacol. 2004;57(6):735\u201341.","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"206_CR64","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1128\/AAC.48.10.3794-3800.2004","volume":"48","author":"S Corvaisier","year":"2004","unstructured":"Corvaisier S, Charpiat B, Mounier C, et al. Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis. Antimicrob Agents Chemother. 2004;48(10):3794\u2013800.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"206_CR65","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1128\/AAC.40.7.1623","volume":"40","author":"H Klinker","year":"1996","unstructured":"Klinker H, Langmann P, Richter E. Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS. Antimicrob Agents Chemother. 1996;40(7):1623\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"206_CR66","first-page":"647","volume":"27","author":"J Couvreur","year":"1980","unstructured":"Couvreur J, Nottin N, Desmonts G. Treatment of congenital toxoplasmosis. Clinical and biological results (author\u2019s transl). Ann Pediatr. 1980;27(10):647\u201352.","journal-title":"Ann Pediatr"},{"key":"206_CR67","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/adc.2004.066514","volume":"2006","author":"DR Schmidt","year":"2006","unstructured":"Schmidt DR, Hogh B, Andersen O, et al. The national neonatal screening programme for congenital toxoplasmosis in Denmark: results from the initial four years, 1999\u20132002. Arch Dis Child. 2006;2006:661\u20135.","journal-title":"Arch Dis Child"},{"issue":"3","key":"206_CR68","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0002-9378(80)90870-4","volume":"136","author":"B Stray-Pedersen","year":"1980","unstructured":"Stray-Pedersen B. A prospective study of acquired toxoplasmosis among 8,043 pregnant women in the Oslo area. Am J Obstet Gynecol. 1980;136(3):399\u2013406.","journal-title":"Am J Obstet Gynecol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-017-0206-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-017-0206-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-017-0206-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T01:35:18Z","timestamp":1570066518000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-017-0206-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,6]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["206"],"URL":"https:\/\/doi.org\/10.1007\/s40268-017-0206-8","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,6]]}}}